Early Outcomes of Prostatic Artery Embolization using n-Butyl Cyanoacrylate Liquid Embolic Agent: A Safety and Feasibility Study

This retrospective study evaluated the feasibility, safety, and short-term effectiveness of prostatic artery embolization (PAE) using n-butyl cyanoacrylate (nBCA) glue embolization in 244 patients from June 2022 through May 2024. Technical success, defined as bilateral glue embolization, was achieved in 95% of cases. The median fluoroscopy time was 22.2 minutes (interquartile range [IQR], 17.1-30.0 minutes), and the median air kerma was 753 mGy (IQR, 417-1,559 mGy). Compared with baseline, statistically significant improvements were observed at 7.1 weeks for the International Prostate Symptom Score (9.5 [SD +/- 6.0] vs 20.5 [SD +/- 6.7]; P < .01), quality of life (1.8 [SD +/- 1.5] vs 4.0 [SD +/- 1.1]; P < .01), Q(max) (10.4 mL/s [SD +/- 6.3] vs 6.1 mL/s [SD +/- 2.5]; P < .01), and prostate grand volume at 6 months (113.3 mL [SD +/- 69.3] vs 156.6 mL [SD +/- 104.6]; P < .01). These results demonstrate the use of nBCA for PAE as a technically feasible and safe option with excellent short-term outcomes.